Bafna Pharmaceuticals
NSE: BAFNAPH · ISIN INE878I01022 · Healthcare
₹472.80+9.25 (+2.00%)
Monday 9 November, 11:14 IST. Delayed. Source: Yahoo Finance.
Price chart
This chart is unavailable right now.
The day
- Previous close
- ₹463.55
- Open
- ₹472.80
- Day high
- ₹472.80
- Day low
- ₹472.80
Listed on NSE since 27 February 2020.
Key numbers
- Market value
- ₹1,075.18 Cr
- P/E (trailing)
- 138.15
- EPS (trailing)
- ₹3.29
- Price to book
- 11.20
- Dividend yield
- 0.00%
- Debt to equity
- 0.39
- Profit margin
- 5.5%
- Beta
- -0.04
- Volume today
- 445
- Average volume
- 7,271
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹115.35 Cr | ₹11.34 Cr |
| FY24 | ₹152.47 Cr | ₹7.35 Cr |
| FY25 | ₹145.86 Cr | ₹4.15 Cr |
| FY26 | ₹150.62 Cr | ₹11.10 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹27 Cr | ₹7.51 L | −97.8% |
| Q4 FY26Jan–Mar 2026Audited | ₹42 Cr | ₹3 Cr | +109.7% |
| Q3 FY26Oct–Dec 2025 | ₹38 Cr | ₹2 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹35 Cr | ₹3 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹35 Cr | ₹3 Cr | – |
| Q4 FY25Jan–Mar 2025Audited | ₹39 Cr | ₹1 Cr | – |
Source: Bafna Pharmaceuticals’s results filed with NSE, standalone (the company alone). Net profit is the share of Bafna Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹85 Cr | ₹80 Cr |
| Investments | ₹5,000 | ₹5,000 |
| Inventories | ₹29 Cr | ₹31 Cr |
| Owed by customers | ₹44 Cr | ₹33 Cr |
| Cash and equivalents | ₹2 Cr | ₹25.44 L |
| Total assets | ₹176 Cr | ₹161 Cr |
| Borrowings | ₹37 Cr | ₹32 Cr |
| Total liabilities | ₹79 Cr | ₹69 Cr |
| Shareholders’ equity | ₹96 Cr | ₹91 Cr |
Source: Bafna Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Bafna Pharmaceuticals
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company offers its products in various dosage forms, including tablets, capsules, and solid orals. It provides various products for cardiovascular and hypertension, potent oncology, anti-infectives, central nervous system, and diabetic related diseases, as well as provision of contract research and manufacturing services. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, and Nigeria. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. The company operates as a subsidiary of SRJR Lifesciences LLP.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Chennai
- Employees
- 339
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Bafna Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Annual General Meeting
Action · ex-date 17 September 2024
- Annual General Meeting
Action · ex-date 20 July 2022
- Annual General Meeting
Action · ex-date 5 August 2021
- Annual General Meeting
Action · ex-date 23 July 2020
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.